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Reply
To the Editor:
Earlier and recent data (cited by the letter of Dr. Schadendorf)
about the combined application of exogenously added histamine
and interleukin (IL) seem to indicate a promising approach in
melanoma therapy. The effect is likely based on an earlier view
(Hellstrand et al, 2001) that histamine suppresses the inhibitory
action of macrophages on natural killer cells.
Our and others' recent and earlier data suggest ®ve things:
1. Regardless of the sometimes debated presence of mast cells in
melanoma tissue, there is endogenous expression of histidine
decarboxylase (HDC) mRNA (thus presence of HDC is proved
not only by western blots, but also by HDC mRNA being
visualized by in situ hybridization) and immunoreactive histamine
within melanoma cells (Haak-Fredscho et al, 2000). This fact and
the amount of HDC is not in direct relation with poor prognosis of
melanoma; however, suppression of melanoma cell growth with
HDC-speci®c antisense oligonucleotides suggests that the involve-
ment of locally produced histamine is hardly questionable.
2. Histamine receptor (HR) 1 agonists directly decrease, whereas
HR2 agonists directly increase proliferation of melanoma cells
(Reynolds et al, 1996; Lazar-Molnar et al, submitted), thus actual
and local ratio between HR1 and HR2 on melanoma cells seems to
be critical for the net outcome of the action of endogenously
produced histamine.
3. HR2 antagonist cimetidine, particularly if combined with a
tamoxifen derivative N,N-diethyl-2-{4-phenylmethyl)phenoxy}-
ethanamine-HCl (DPPE) (Brandes et al, 1991), strongly decreases
tumor mass and increases survival of immunode®cient SCID xeno-
transplanted with human melanoma cell line (Szincsak et al, in
press).
4. There are abundant clinical data on the bene®cial effect of HR2
antagonists on carcinoma (Nielsen, 1996; Bolton et al, 2000).
5. Concerning the interactions with local immune response,
reciprocal inhibitory interactions are found between histamine
and interferon g (Horvath et al, 1999; Heninger et al, 2000).
Furthermore, histamine and locally produced IL-6 are mutually
stimulatory (Lazar-Molnar et al, 2000; Lazar-Molnar et al, submit-
ted). This fact further emphasizes the role of local histamine, as IL-6
(partially generated by the melanoma cells themselves) is also one of
the multiple growth factors for melanoma depending on the
metastatic potential of the tumor. Interestingly, IL-6 in¯uences the
local expression pattern of histamine receptors, this fact provides a
further factor in the autocrine and paracrine effect of histamine on
melanoma cells.
In conclusion, impressive data suggest that therapeutically
administered histamine potentiates the effect of IL-2, as an adjuvant
or by another, not yet discovered mechanism. Nevertheless, this is
not in controversy with our view that locally produced histamine
acting on paracrine or autocrine way in¯uence tumor growth on a
receptor (i.e., signal pathway)-dependent manner and endogen-
ously produced and acting histamine shifts local T cell response
toward Th2 polarization.
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